TALZENNA
Drug
PFIZER INC.
Total Payments
$162.3M
Transactions
10,652
Doctors
1,105
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $28.8M | 1,365 | 218 |
| 2023 | $20.9M | 1,487 | 242 |
| 2022 | $22.6M | 1,319 | 90 |
| 2021 | $28.3M | 1,485 | 130 |
| 2020 | $35.5M | 1,801 | 124 |
| 2019 | $18.4M | 2,258 | 575 |
| 2018 | $7.7M | 937 | 62 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $156.6M | 7,183 | 96.5% |
| Consulting Fee | $3.3M | 907 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 706 | 1.1% |
| Travel and Lodging | $238,025 | 496 | 0.1% |
| Honoraria | $221,940 | 104 | 0.1% |
| Grant | $154,147 | 3 | 0.1% |
| Food and Beverage | $55,549 | 704 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $14,125 | 10 | 0.0% |
| Education | $5,805 | 539 | 0.0% |
Payments by Type
Research
$156.6M
7,183 transactions
General
$5.7M
3,469 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES | PFIZER INC. | $32.3M | 0 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | PFIZER INC. | $29.3M | 0 |
| TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | PFIZER INC. | $27.0M | 0 |
| A PHASE 1 OPEN LABEL CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | PFIZER INC. | $9.5M | 0 |
| A PHASE IBII STUDY OF TALAZOPARIB AND AXITINIB IN METASTATIC RENAL CELL CARCINOMA | PFIZER INC. | $8.4M | 0 |
| MODULAR PHASE IB HYPOTHESISTESTING BIOMARKERDRIVEN TALAZOPARIB COMBINATION TRIAL TALACOM | PFIZER INC. | $8.4M | 0 |
| A RANDOMIZED PHASE I AND II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN AND YOUNG ADULTS WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA | PFIZER INC. | $6.4M | 0 |
| 2018 ASPIRE BREAST CANCER BY INVITE ONLY PHASE 2 TRIAL WITH SAFETY RUNIN OF GEDATOLISIB PLUS TALAZOPARIB IN ADVANCED TRIPLE NEGATIVE OR BRCA1 OR 2 POSITIVE HER2 NEGATIVE BREAST CANCERS | PFIZER INC. | $3.9M | 0 |
| A PHASE 1B 2 STUDY OF INTERMITTENT TALAZOPARIB PLUS HIGH DOSE TEMOZOLOMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | PFIZER INC. | $2.9M | 1 |
| A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EXTENSIVESTAGE SMALL CELL LUNG CANCER TRIOUS L07 | PFIZER INC. | $2.4M | 0 |
| FULL PHASE 1B STUDY TO EVALUATE SAFETY AND EFFICACY OF TALAZOPARIB IN COMBINATION WITH SACITUZUMAB GOVITECAN FOR PATIENTS WITH METASTATIC TRIPLENEGATIVE BREAST CANCER | PFIZER INC. | $2.3M | 0 |
| PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER | PFIZER INC. | $2.0M | 0 |
| FULL TALAZOPARIB AND AVELUMAB IN GENOMICALLY DEFINED METASTATIC RENAL CELL CARCINOMA | PFIZER INC. | $1.6M | 0 |
| PHASE II STUDY OF THE PARP INHIBITOR BMN 673 IN ADVANCED CANCER PATIENTS WITH SOMATIC ALTERATIONS IN BRCA12 OR A HOMOLOGOUS RECOMBINATION DEFECT | PFIZER INC. | $1.5M | 0 |
| A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED ANDOR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE | MEDIVATION INC. | $1.4M | 0 |
| WI245157 MODULAR PHASE IB HYPOTHESISTESTING BIOMARKERDRIVEN TALAZOPARIB COMBINATION TRIAL TALACOM | PFIZER INC. | $1.4M | 0 |
| S1400G A PHASE II STUDY OF TALAZOPARIB BMN 673 IN PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY HRRD POSITIVE STAGE IV SQUAMOUS CELL LUNG CANCER LUNGMAP SUBSTUDY | PFIZER INC. | $1.1M | 0 |
| A PHASE 2 OPENLABEL 2ARM RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANEBASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT ENZALUTAMIDE ANDOR ABIRATERONE ACETATEPREDNISONE | PFIZER INC. | $883,628 | 0 |
| A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT | PFIZER INC. | $768,454 | 0 |
| A PHASE IAIB STUDY OF TALAZOPARIB IN COMBINATION WITH TAZEMETOSTAT IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER MCRPC | PFIZER INC. | $720,000 | 0 |
Top Doctors Receiving Payments for TALZENNA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $156.4M | 6,657 |
| , M.D | Diagnostic Radiology | Boston, MA | $420,845 | 64 |
| , MD | Diagnostic Radiology | Boston, MA | $406,800 | 68 |
| , MD | Body Imaging | Boston, MA | $372,640 | 98 |
| , MD | Nuclear Medicine | Boston, MA | $361,035 | 69 |
| , MD | Diagnostic Radiology | New York, NY | $352,255 | 61 |
| , M.D | Diagnostic Radiology | Fort Worth, TX | $293,695 | 91 |
| , M.D | Diagnostic Radiology | Newton, MA | $292,590 | 93 |
| , M.D | Urology | Los Angeles, CA | $135,755 | 30 |
| , DR | Urology | Myrtle Beach, SC | $131,230 | 90 |
| , M.D | Hematology & Oncology | New Orleans, LA | $128,233 | 47 |
| , MD | Internal Medicine | Salt Lake City, UT | $94,824 | 90 |
| , MD | Internal Medicine | Santa Monica, CA | $80,891 | 84 |
| , MD | Internal Medicine | San Francisco, CA | $79,636 | 83 |
| , M.D | Medical Oncology | Houston, TX | $73,030 | 72 |
| , M.D | Hematology & Oncology | Gilbert, AZ | $71,130 | 53 |
| , MD | Urology | Orange, CA | $56,774 | 55 |
| , M.D | Hematology & Oncology | Cary, NC | $56,220 | 63 |
| , MD | Urology | Tucson, AZ | $55,647 | 46 |
| , M.D | Medical Oncology | Los Angeles, CA | $55,221 | 51 |
| , M.D | Hematology & Oncology | Dallas, TX | $54,330 | 47 |
| , MD | Medical Oncology | San Antonio, TX | $52,148 | 23 |
| , M.D | Urology | Denver, CO | $51,724 | 47 |
| , M.D | Urology | Durham, NC | $48,825 | 20 |
| , M.D | Medical Oncology | New Orleans, LA | $45,363 | 21 |
Ad
Manufacturing Companies
- PFIZER INC. $160.0M
- MEDIVATION INC. $1.9M
- Pfizer Inc. $315,159
- PFIZER INTERNATIONAL LLC $14,331
- MEDIVATION LLC. $7,376
- PFIZER CHILE S.A. $2,800
- PFIZER PHARMACEUTICALS LLC $175.47
Product Information
- Type Drug
- Total Payments $162.3M
- Total Doctors 1,105
- Transactions 10,652
About TALZENNA
TALZENNA is a drug associated with $162.3M in payments to 1,105 healthcare providers, recorded across 10,652 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2018 to 2024. In 2024, $28.8M was paid across 1,365 transactions to 218 doctors.
The most common payment nature for TALZENNA is "Unspecified" ($156.6M, 96.5% of total).
TALZENNA is associated with 20 research studies, including "A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES" ($32.3M).